INTRODUCTION
Urokinase-type plasminogen activator (uPA) 1 is a serine proteinase that activates diverse cell-signaling pathways by binding to its cell-surface receptor, uPAR (1) (2) (3) . Because uPAR is glycosylphosphatidylinositol-anchored and thus lacks transmembrane and intracytoplasmic domains (4), it is assumed that the complete signaling receptor is a uPAR-containing protein complex. The function of uPA may be to induce uPAR conformational change so that the required interactions with other plasma membrane proteins are established and signaling is initiated (2) .
In support of this hypothesis, soluble uPAR mimics many of the activities of uPA, probably because soluble uPAR adopts the same conformation as plasma membrane-associated uPAR after complex formation with uPA (5-7). uPAR also may regulate cell-signaling by uPA-independent pathways (8, 9) . How the cell integrates uPA-dependent and -independent uPAR signals remains to be determined.
In many cell types, binding of uPA to uPAR results in activation of the mitogen-activated protein (MAP) kinase, extracellular signal-regulated kinase (ERK) (7, (10) (11) (12) (13) . This signaling response may be of central importance because the level of activated ERK controls many physiologic processes, including cell growth, differentiation, apoptosis, migration, and in cancer, invasion and metastasis (1) . uPA-induced ERK activation in MCF-7 breast cancer cells is entirely dependent on the small GTPase, Ras (7), which presumably functions through the downstream effectors, Raf and MAP kinase kinase (MEK) (14) . In aggressive cancer cells, endogenouslyproduced uPA and uPAR may form a self-contained autocrine pathway, which serves as a major determinant of the basal level of ERK activation, in the absence of exogenous stimulants (15-17).
uPA promotes migration of MCF-7 and HT 1080 cells, on serum or vitronectin-coated surfaces, by a mechanism that requires ERK (9, 10) . In this pathway, ERK activates myosin light by guest on August 17, 2017 http://www.jbc.org/ Downloaded from 4 chain kinase (MLCK), which induces serine-phosphorylation of myosin II regulatory light chain and thereby promotes contraction of the actomyosin cytoskeleton (9, 18) . Why increased cytoskeletal contractility is important for the migrating cell remains incompletely understood; however, it is thought that this activity facilitates retraction of the cell tail. uPAR-initiated signaling is also important in the mechanism by which uPA promotes smooth muscle cell migration; however, in these cells, the response is blocked by inhibitors of a distinct signaling pathway that includes the Janus kinase, Tyk2, and phosphatidylinositol 3-kinase (PI3K) (19) . The activity of the Ras-ERK pathway in smooth muscle cell migration has not been explored. Nevertheless, the function of Tyk2 and PI3K in smooth muscle cell migration (19) raises the possibility that distinct signaling pathways may be preeminent in determining physiologic responses to uPA in different cell types.
The focus of this study is the function of the small GTPase, Rho, and the major Rho effector, Rho kinase (also known as p160ROCK), in uPA-promoted MCF-7 and HT 1080 cell migration. RhoA and homologous proteins in the Rho family function primarily in processes that require remodeling of the actin cytoskeleton (20) . In stationary cells, RhoA promotes the formation of actin stress fibers and clustering of proteins in focal adhesions (20) (21) (22) (23) . However, recent studies suggest that RhoA, RhoC, and Rho kinase also may be important in cell migration and cancer invasion (24) (25) (26) (27) (28) (29) . How these proteins promote cell migration is incompletely understood. By inactivating myosin light chain phosphatase, Rho kinase may complement the function of MLCK in promoting myosin regulatory light chain phosphorylation and actomyosin contractility (28, 30) . Rho kinase also activates a downstream pathway that culminates in the inactivation of cofilin, an actin depolymerizing agent (31) . Furthermore, Rho kinase may 5 regulate the avidity of cellular integrins for the extracellular matrix, allowing the migrating cell to retract its tail (28, 29) .
We undertook these studies due to the apparent overlap in the downstream targets of the Cell Migration Assays -Migration of MCF-7 and HT 1080 cells was studied using 6.5
mm Transwell chambers with 8 µm pores (Costar), as previously described (10) . The Transwell membranes were coated with 20% FBS or type I collagen (25 µg/mL) (BD Biosciences) on the underside only. Both membrane surfaces were then blocked with 5 mg/ml BSA for 2 h at 37 o C.
Cells (10 5 in 100 µL) in serum-free medium were pre-treated first with PD098059 (50 µM) or Y-27632 (25 µM) for 15 min in suspension, and then with DIP-uPA or EGF for an additional 15 min. The cells then were added to the upper chamber of each Transwell unit in the presence of the same agents. The lower chamber was supplemented with DIP-uPA or EGF when these agents were added to the top chamber. FBS (10%) was also added to the lower chamber in MCF-7 cell migration experiments. Migration was allowed to occur for 6 h at 37° C. MCF-7 cell migration to the underside of the membrane was determined by counting cells stained with
Diff-Quik C (Dade Diagnostics) (10) . HT 1080 cell migration was determined by crystal violet staining, as previously described (9).
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In some experiments, MCF-7 cells were transiently transfected to express constitutively active MEK1, RhoA N19, or β3 integrin subunit (2 µg of each construct) by incubation with Effectine (Qiagen) for 24 h. The same cells were co-transfected to express GFP (0.5 µg).
Transfection and co-transfection efficiencies were determined as previously described (9) . Importantly, co-transfection efficiencies were always approximately 100%. Migration experiments were performed as described above, except that Biocoat cell culture inserts (Becton Dickinson) were used instead of Transwell chambers. Cell migration was determined by counting greenfluorescing cells.
ERK Phosphorylation Assay -MCF-7 cells were cultured on 6-well plates until 80-90% confluent, and then serum-starved for 24 h. When indicated, the cells were preincubated with PD098059 (50 µM) or Y27632 (25 µM) for 15 min. DIP-uPA (10 nM) was then added for 2 min. Cell extracts were prepared in 10 mM HEPES, 150 mM NaCl, 2 mM EDTA, 1% (v/v) NP-40, pH 7.5, containing protease inhibitor cocktail and sodium orthovanadate (1 mM). The protein concentration in each extract was determined by fluoraldehyde assay. Equal amounts of each extract were then subjected SDS-PAGE on 10% slabs, electrotransferred to polyvinylidene diflouride (PVDF) membranes, and probed for phosphorylated and total ERK by immunoblot analysis.
To study ERK phosphorylation in MCF-7 cells that were transiently transfected with constructs encoding constitutively active MEK1 (2 µg) and/or RhoA N19 (2 µg), cells were cotransfected to express HA-tagged ERK (0.5 µg) using Effectene (Qiagen). Cells were maintained in serum-containing media for 24 h to optimize transfection and expression, and then serum- 
RESULTS

Rho kinase is essential for uPA-stimulated cell migration -We previously demonstrated
an essential role for the Ras-ERK pathway in uPA-stimulated MCF-7 breast cancer cell and HT 1080 fibrosarcoma cell migration (10) . Synthetic inhibitors and dominant-negative mutants of MEK1 and H-Ras, which prevent ERK activation, blocked cell migration in response to uPA (9).
Furthermore, dominant-negative mutants of signaling proteins that frequently couple signaling receptors to H-Ras, including focal adhesion kinase, c-Src, and Shc, also blocked cell migration in response to uPA (7). The same agents had no effect on cell migration in the absence of uPA.
Taken together, these results could be interpreted to indicate an exclusive role for the Ras-ERK pathway in uPA-stimulated cell migration.
In cell migration, the Rho-Rho kinase pathway and the Ras-ERK pathway may affect similar processes, such as tail retraction (18, 28, 29) . To assess the function of the Rho-Rho kinase pathway in uPA-stimulated cell migration, we studied MCF-7 and HT 1080 cells in
Transwell membranes that were pre-coated with serum for 2 h. Under these conditions, the membranes become coated primarily with vitronectin, which serves as the major cell attachment and spreading factor (33) . Our previous work indicates that identical results are obtained when membranes are coated with serum or purified vitronectin (7, 9, 10) . Cells were added to the upper chamber and allowed to migrate for 6 h. Fig. 1A shows that DIP-uPA promoted MCF-7 cell migration, as previously reported (10) . When cells were pre-treated with the MEK inhibitor, PD098059 (50 µM), the response to uPA was entirely blocked. PD098059 had no effect on cell migration in the absence of uPA, as anticipated because, in unstimulated MCF-7 cells, the level of activated ERK is extremely low (10). uPA stimulated HT 1080 cell migration and PD098059 (50 µM) completely blocked this response, as anticipated (9) . PD098059 had no effect on HT 1080 cell migration in the absence of uPA. Similarly, Y-27632 (25 µM) blocked the effects of uPA on HT 1080 cell migration and had no effect on cell migration in the absence of uPA. When HT 1080 cells were treated simultaneously with PD098059 and Y-27632, at concentrations that were sufficient to independently block uPA-stimulated cell migration, the combination of drugs was no more effective than either agent added independently.
Other ERK-activating agents require the Rho-Rho kinase pathway to promote MCF-7
cell migration -We next sought to determine whether Rho kinase is important when MCF-7 cell migration is stimulated by agents other than uPA. EGF activates multiple signaling pathways, including the Ras-ERK pathway, by binding to its receptor tyrosine kinase (34) . As shown in The effects of uPA on RhoA activity -To assess the effects of uPA on RhoA activity, we used a pull-down assay with the fusion protein, GST-TRBD, which recognizes only GTP-bound Rho (32) . MCF-7 cells were treated with DIP-uPA (10 nM) for up to 30 min or with the wellcharacterized Rho activating agent, LPA (10 µM) for 1 min. Cell extracts were affinity-precipitated with GST-TRBD and then studied by immunoblot analysis using a RhoA-specific antibody. LPA induced an 8.4±1.3-fold increase in GTP-RhoA (n=6, p<0.01), thus providing a positive control (Fig. 3) . A modest increase in GTP-RhoA was sometimes observed in MCF-7 cells that were treated with DIP-uPA; however, the increase in GTP-RhoA was substantially lower than that observed with LPA and not statistically significant at the p<0.1 level (n=6). When MCF-7 cells were transfected to express constitutively active MEK1, increased phosphorylation of HA-ERK1 was observed (Fig. 4B) . PD098059 decreased the level of phosphorylated HA-ERK1 in these cells, whereas Y-27632 had no effect. RhoA N19 not only failed to inhibit the effects of active MEK1 on HA-ERK1 phosphorylation but also independently promoted HA-ERK1 phosphorylation, as was observed with Y-27632. These results indicate that Y-27632 and RhoA N19 block uPA-and MEK1-stimulated cell migration by a mechanism that does not involve inhibition of ERK activation. Furthermore, the finding that Y-27632 and RhoA N19 independently promote ERK activation provides further evidence that ERK activation alone is insufficient to promote cell migration when Rho kinase is antagonized.
ERK-independent pathways for stimulating MCF-7 cell migration are not inhibited by
antagonists of the Rho-Rho kinase pathway -The rate of MCF-7 cell migration and the effects of uPA on migration depend on the extracellular matrix protein which forms the migration surface and the integrins that are used by the cell to adhere to the matrix. MCF-7 cells adhere to vitronectin and migrate on vitronectin-coated surfaces using the integrins, α v β 5 and α v β 1 (9) .
When these cells are transfected to express β3 integrin subunit, α v β 3 forms on the cell surface and becomes functional in cell adhesion and migration. We previously demonstrated that β3-expressing MCF-7 cells migrate at an increased rate on serum-and vitronectin-coated surfaces, in the absence of stimulatory agents such as uPA, and that the rate at which these cells migrate is not affected by uPA or inhibitors of MLCK (9, 38) .
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To confirm that β3 expression promotes MCF-7 cell migration on serum-coated surfaces, we compared cells that were transiently transfected to express GFP and β3 or GFP alone. As shown in Fig. 5A , the β3-expressing cells migrated at a rate that was increased 1.8-fold. In experiments with MCF-7 cells that were cloned for stable β3 expression (34), DIP-uPA failed to promote cell migration and PD098059 did not inhibit migration, confirming out earlier results (9) . In these same cells, Y-27632 also failed to affect cell migration. As an additional test of this hypothesis, we studied MCF-7 cell migration on type I collagen. We previously demonstrated that MCF-7 cell migration is significantly accelerated on collagen-coated surfaces, as opposed to serum-coated surfaces, and that uPA does not stimulate cell migration on collagen (9) . As shown in Fig. 5C , we confirmed these results and demonstrated that Y-27632 does not affect MCF-7 cell migration on collagen, in the presence or absence of uPA.
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When MCF-7 cells were transfected to express constitutively-active MEK1, cell migration on collagen was not increased, demonstrating that ERK activation does not support this response (Fig. 5D ). PD098059 did not inhibit the migration of active MEK1 expressing cells on collagen. Similarly, antagonists of the Rho-Rho kinase pathway, including Y-27632 and RhoA N19, failed to regulate the migration of MEK1-expressing MCF-7 cells on collagen. These same antagonists significantly inhibited the migration of MEK1-expressing cells on serum-coated membranes (compare Fig. 5D with Fig. 2B ). RhoA N19 also had no effect on MCF-7 cell migration on collagen in the absence of active MEK1.
DISCUSSION
The studies presented here demonstrate that the Ras-ERK and Rho-Rho kinase pathways function independently but in a complementary manner to support MCF-7 and HT 1080 cell migration. This cooperation is observed with multiple agents that activate ERK, including uPA, EGF, and constitutively active MEK1. In the absence of these agents, the level of activated ERK in MCF-7 cells is very low and various agents that antagonize the Ras-ERK pathway are ineffective at inhibiting cell migration (9, 10) . By contrast, the constitutive activity of the Rho-Rho kinase pathway appears to be sufficient in supporting ERK-promoted MCF-7 cell migration. If indeed uPA promotes RhoA activation at all, the degree of activation is very low compared with that induced by the well-characterized activator, LPA.
Although the Ras-ERK and Rho-Rho kinase pathways function in a cooperative manner, our evidence suggests that cross-talk between the two pathways is not responsible. PD098059 There is considerable evidence that the Ras-ERK pathway plays a central role in uPARregulated cell physiology (1). The uPA-uPAR system and the Ras-ERK pathway may impact on cell migration, cell growth and apoptosis. In MCF-7 cell migration, MLCK functions as a critical downstream effector of ERK (9, 18) . However, in other cell types, different signaling pathways may be essential for uPA-induced changes in cell physiology. For example, in vascular smooth muscle cells, uPA activates PI3K via a Tyk2-dependent pathway and this response is required for uPA-stimulated cell migration (19) . Furthermore, the ecto-protein kinase, casein kinase 2, may be required for uPA-induced smooth muscle cell proliferation, presumably based on its ability to phosphorylate nucleolin so that the nucleolin translocates into the cell (39).
These studies raise the possibility that different uPA-activated cell signaling pathways may be responsible for specific physiologic responses, such as enhanced migration or increased proliferation, in different cell types. Alternatively, the apparent importance of different signaling cascades may reflect the fact that antagonizing any one of multiple pathways is sufficient to eliminate a response entirely.
In both MCF-7 and HT 1080 cells, we found that antagonizing either the Ras-ERK or Rho-Rho kinase pathway was sufficient to completely block a cellular response which we had previously attributed exclusively to the Ras-ERK pathway (9, 10) . These new results indicate 
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The lane labeled "PD" was pre-treated with PD098059 and then with DIP-uPA. Active GTPbound Rho was affinity-precipitated with GST-TRBD and the amount of RhoA in the precipitates was determined by immunoblot analysis. The original cell extracts were also studied by immunoblot analysis using the same antibody to determine total RhoA levels. Panel B.
Immunoblots were analyzed by densitometry. The results of six separate experiments were then averaged to generate the bar graph that is shown (mean±SEM). The bar labeled "PD" was pre- 
